Another FDA 483 At Ranbaxy’s Toansa API Site May Hold Up Key Launches
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy’s compliance woes keep coming with the latest news that its crucial API facility was cited as a follow-up to FDA inspections. The fate of several of its key drugs hangs in the balance.